Insmed Historical Cash Flow
| INSM Stock | USD 68.32 1.04 1.55% |
Analysis of Insmed cash flow over time is an excellent tool to project Insmed Inc future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 11.1 M or Other Non Cash Items of 94.7 M as it is a great indicator of Insmed ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Insmed Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Insmed Inc is a good buy for the upcoming year.
Insmed |
About Insmed Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Insmed balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Insmed's non-liquid assets can be easily converted into cash.
Insmed Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Insmed Inc to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Insmed operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Insmed's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Insmed Inc current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. At this time, Insmed's Stock Based Compensation is very stable compared to the past year. As of the 3rd of November 2024, Net Borrowings is likely to grow to about 401.2 M, though Free Cash Flow is likely to grow to (522.1 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 52.0M | 6.5M | 90.2M | 94.7M | Depreciation | 14.2M | 10.3M | 10.6M | 11.1M |
Insmed cash flow statement Correlations
Click cells to compare fundamentals
Insmed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Insmed cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (7.6M) | 45.3M | 184.0M | 357.3M | (591.7M) | (562.1M) | |
| Free Cash Flow | (292.9M) | (226.2M) | (370.6M) | (410.3M) | (549.5M) | (522.1M) | |
| Change In Working Capital | (63.0M) | (3.0M) | (58.6M) | 6.6M | (39.2M) | (37.3M) | |
| Begin Period Cash Flow | 495.1M | 487.4M | 532.8M | 716.8M | 1.1B | 1.1B | |
| Other Cashflows From Financing Activities | 285.3M | 26.1M | 567.7M | 983.3M | 17.2M | 16.3M | |
| Depreciation | 10.2M | 14.2M | 14.2M | 10.3M | 10.6M | 11.1M | |
| Other Non Cash Items | 29.5M | 27.4M | 52.0M | 6.5M | 90.2M | 94.7M | |
| Capital Expenditures | 42.3M | 6.8M | 7.3M | 9.9M | 13.3M | 14.0M | |
| Total Cash From Operating Activities | (250.6M) | (219.3M) | (363.3M) | (400.4M) | (536.2M) | (509.4M) | |
| Net Income | (254.3M) | (294.1M) | (434.7M) | (481.5M) | (749.6M) | (712.1M) | |
| Total Cash From Financing Activities | 285.3M | 271.0M | 612.5M | 793.3M | 168.4M | 158.8M | |
| End Period Cash Flow | 487.4M | 532.8M | 716.8M | 1.1B | 482.4M | 506.5M | |
| Change To Liabilities | (3.2M) | 24.9M | (7.6M) | 50.0M | 57.5M | 60.4M | |
| Stock Based Compensation | 27.0M | 37.4M | 46.0M | 57.7M | 74.8M | 78.5M | |
| Total Cashflows From Investing Activities | (42.3M) | (6.8M) | (64.3M) | (34.6M) | (31.1M) | (29.6M) | |
| Change To Account Receivables | (13.7M) | 2.7M | (8.1M) | (6.4M) | (12.0M) | (11.4M) | |
| Change To Inventory | (21.3M) | (21.2M) | (17.5M) | (1.7M) | (13.6M) | (14.3M) | |
| Sale Purchase Of Stock | 280.8M | 271.9M | 291.9M | 311.7M | 358.4M | 181.5M | |
| Investments | (42.3M) | (6.8M) | (50.3M) | (34.6M) | (205.1M) | (194.8M) | |
| Change Receivables | (13.7M) | 2.7M | (8.1M) | (6.4M) | (5.8M) | (6.1M) | |
| Cash And Cash Equivalents Changes | (7.6M) | 45.3M | 185.0M | 358.3M | 412.0M | 432.6M | |
| Cash Flows Other Operating | 3.4M | 16.6M | 19.3M | (21.4M) | (24.6M) | (23.3M) | |
| Change To Netincome | 27.0M | 36.2M | 71.0M | 46.3M | 53.2M | 28.4M | |
| Change To Operating Activities | (23.0M) | (14.3M) | (25.4M) | (35.3M) | (31.8M) | (30.2M) | |
| Exchange Rate Changes | 103K | (45K) | (4K) | 494K | 568.1K | 596.5K | |
| Issuance Of Capital Stock | 261.1M | 245.9M | 269.9M | 292.2M | 296.8M | 250.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.